Paris, France… Ethypharm, a pharmaceutical technology based company, announced that United States Food and Drug Administration (FDA) recently completed two Inspections at its manufacturing facilities, located in Grand Quevilly and Chateauneuf en Thymerais, near Paris, France, for the general review of cGMP’s compliance and the further launch of three products on the American market.
Further to Ethypharm’s responses to the FDA 483 forms, the FDA concluded to maintain the agreement on the existing US products.
